Aspen Neuroscience Inc. (ASPE)
Snapshot
- 1 week
- -12.4%-10.7% vs SPY
- Market cap
- $379.2M
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Aspen Neuroscience Inc. (ASPE). Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquarte…
- Damien McDevittPresident, CEO & DirectorUSD 954K
- Kim RaineriChief Technology OfficerUSD 622K
- Faheem HasnainExecutive ChairmanUSD 35K
- Jennifer WhitakerVice President of Human Resources
- Samantha MurphySenior Vice President of Corporate Development
- Xiaokui ZhangChief Scientific Officer
Snapshot
Price & returns1 week -12.4%
- 1 week
- -12.4%-10.7% vs SPY
Valuationmarket cap $379.2M
- Market cap
- $379.2M
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Aspen Neuroscience Inc. (ASPE). Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquarte…
- Damien McDevittPresident, CEO & DirectorUSD 954K
- Kim RaineriChief Technology OfficerUSD 622K
- Faheem HasnainExecutive ChairmanUSD 35K
- Jennifer WhitakerVice President of Human Resources
